Brief: Immunoprecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing A Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated With Poor Prognosis And Survival Rates
23/03/2023 12:23
March 23 (Reuters) - Immunoprecise Antibodies Ltd
IPA.O :
* IMMUNOPRECISE PRESENTS NOVEL T-CELL ENGAGING BISPECIFIC
ANTIBODIES ADDRESSING A UNIQUE ONCOLOGICAL TARGET, TROPOMYOSIN
RECEPTOR KINASE B, ASSOCIATED WITH POOR PROGNOSIS AND SURVIVAL
RATES
* IMMUNOPRECISE ANTIBODIES LTD - HAS FILED A PROVISIONAL
PATENT
APPLICATION TO UNITED STATE PATENT AND TRADEMARK OFFICE
Source text for Eikon: ID:nBw9kG13ma
Further company coverage: IPA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mindwalk Holdings
See all newsBrief: Mindwalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp reports results for the quarter ended July 31 - Earnings Summary
Canada's MindWalk Q1 net loss widens on higher sales, marketing expenses
MindWalk Holdings Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: MindWalk Showcases Reefiq™ For Ai Drug Discovery At AMD Advancing Ai